Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone...

Descripción completa

Detalles Bibliográficos
Autores principales: Tommasi, Chiara, Bellagamba, Rita, Tempestilli, Massimo, D'Avolio, Antonio, Gallo, Anna L, Ivanovic, Jelena, Nicastri, Emanuele, Pucillo, Leopoldo P, Narciso, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112458/
https://www.ncbi.nlm.nih.gov/pubmed/21600016
http://dx.doi.org/10.1186/1475-2875-10-141
_version_ 1782205752820105216
author Tommasi, Chiara
Bellagamba, Rita
Tempestilli, Massimo
D'Avolio, Antonio
Gallo, Anna L
Ivanovic, Jelena
Nicastri, Emanuele
Pucillo, Leopoldo P
Narciso, Pasquale
author_facet Tommasi, Chiara
Bellagamba, Rita
Tempestilli, Massimo
D'Avolio, Antonio
Gallo, Anna L
Ivanovic, Jelena
Nicastri, Emanuele
Pucillo, Leopoldo P
Narciso, Pasquale
author_sort Tommasi, Chiara
collection PubMed
description The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.
format Online
Article
Text
id pubmed-3112458
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31124582011-06-12 Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis Tommasi, Chiara Bellagamba, Rita Tempestilli, Massimo D'Avolio, Antonio Gallo, Anna L Ivanovic, Jelena Nicastri, Emanuele Pucillo, Leopoldo P Narciso, Pasquale Malar J Case Report The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450. BioMed Central 2011-05-21 /pmc/articles/PMC3112458/ /pubmed/21600016 http://dx.doi.org/10.1186/1475-2875-10-141 Text en Copyright ©2011 Tommasi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Tommasi, Chiara
Bellagamba, Rita
Tempestilli, Massimo
D'Avolio, Antonio
Gallo, Anna L
Ivanovic, Jelena
Nicastri, Emanuele
Pucillo, Leopoldo P
Narciso, Pasquale
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
title Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
title_full Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
title_fullStr Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
title_full_unstemmed Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
title_short Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
title_sort marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112458/
https://www.ncbi.nlm.nih.gov/pubmed/21600016
http://dx.doi.org/10.1186/1475-2875-10-141
work_keys_str_mv AT tommasichiara markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT bellagambarita markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT tempestillimassimo markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT davolioantonio markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT galloannal markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT ivanovicjelena markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT nicastriemanuele markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT pucilloleopoldop markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis
AT narcisopasquale markedincreaseinetravirineandsaquinavirplasmaconcentrationsduringatovaquoneproguanilprophylaxis

Ejemplares similares